Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals have entered into research collaboration with Brigham and Women's Hospital to evaluate the anti-fibrotic effects effects of some of the company's novel, carbohydrate compounds to treat acute and chronic kidney disease.
Subscribe to our email newsletter
Pro-Pharmaceuticals engages in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections.
Anatole Klyosov,chief scientist, Pro-Pharmaceuticals, said: “Collaborating with Brigham and Women’s Hospital represents an exciting opportunity to partner with a premier academic hospital to further explore the use of our novel compounds to treat kidney fibrosis.”
According to the National Kidney Foundation, approximately 12 million people suffer from kidney fibrosis.